Endometriosis Pain Pipeline Analysis Report 2026

Report Coverage

The Endometriosis Pain Pipeline Analysis Report by Expert Market Research gives comprehensive insights into endometriosis pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for endometriosis pain. The endometriosis pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The endometriosis pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with endometriosis pain treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to endometriosis pain.

Read more about this report - Request a Free Sample

Endometriosis Pain Pipeline Outlook

The Endometriosis Pain Pipeline Outlook reflects growing momentum toward both hormonal and non-hormonal therapies aimed at improving long-term symptom control. In March 2026, EndoCyclic Therapeutics received U.S. FDA IND clearance for ENDO-205, a first-in-class non-hormonal targeted peptide therapy designed to eliminate endometriosis lesions and relieve pain, enabling initiation of a Phase I clinical trial. The pipeline is also supported by continued development of next-generation GnRH antagonists, monoclonal antibodies, and combination therapies, while established agents such as MYFEMBREE® continue expanding their clinical use in managing moderate-to-severe endometriosis-associated pain.

Endometriosis Pain Epidemiology

Endometriosis is a chronic gynecological disorder affecting an estimated 190 million women and girls worldwide, representing approximately 10% of women of reproductive age. Chronic pelvic pain is the most common manifestation, significantly impairing quality of life and daily functioning. The condition is also strongly associated with dysmenorrhea, dyspareunia, and infertility, with 30%-50% of affected women experiencing infertility. Delayed diagnosis remains common because symptoms often overlap with other pelvic disorders, underscoring the need for earlier detection and more effective therapies to reduce the long-term burden of endometriosis-associated pain.

Endometriosis Pain – Pipeline Therapeutic Assessment

Endometriosis Pain Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total endometriosis pain clinical trials. Early Phase I (0.00%), Phase I (8.00%), Phase II (41.60%), Phase III (30.40%), and Phase IV (20.00%) collectively reflect the distribution of pipeline candidates across different stages of clinical development.

Endometriosis Pain Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the endometriosis pain pipeline analysis include small molecules, monoclonal antibodies, and peptides. The endometriosis pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for endometriosis pain. In January 2026, Hope Medicine (Nanjing) Co., Ltd. announced that the first patient was dosed in its global Phase II clinical trial evaluating HMI-115, a prolactin receptor (PRLR) monoclonal antibody, for endometriosis-associated pain. HMI-115 is designed as a non-hormonal therapy that targets prolactin signaling to reduce inflammation and lesion activity while avoiding estrogen suppression, representing a novel therapeutic approach for women with moderate-to-severe endometriosis pain.

Endometriosis Pain Clinical Trials – Key Players

The EMR report for the endometriosis pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed endometriosis pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in endometriosis pain clinical trials:

• Hope Medicine (Nanjing) Co., Ltd.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• AbbVie
• Sumitomo Pharma Switzerland GmbH
• Insel Gruppe AG
• Bayer AG
• ObsEva SA
• Pfizer Inc.
• Myovant Sciences GmbH
• Celmatix Inc.
• Forendo Pharma Ltd.
• Evotec SE

Endometriosis Pain – Emerging Drugs Profile

Key Questions Answered in the Endometriosis Pain Pipeline Insight Report

• Which companies/institutions are leading the endometriosis pain drug development?
• Which company is leading the endometriosis pain pipeline development activities?
• What is the current endometriosis pain commercial assessment?
• What are the opportunities and challenges present in the endometriosis pain pipeline landscape?
• What is the efficacy and safety profile of endometriosis pain pipeline drugs?
• Which company is conducting major trials for endometriosis pain drugs?
• Which companies/institutions are involved in endometriosis pain collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in endometriosis pain?

Reasons To Buy This Report

The Endometriosis Pain Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for endometriosis pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into endometriosis pain collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Endometriosis Treatment Market

Endometrial Ablation Market

Endometriosis Market